StockData
Aquestive Therapeutics, Inc. logo

Aquestive Therapeutics, Inc. (AQST) stock

AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 3/30
$3.70−0.06 (-1.60%)

Close on Nov 17, 2026Market cap $464.39MP/E –Yield –

Aquestive Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Aquestive Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$52.23M. For fiscal 2025 it was -$70.50M. The highest annual figure on record is $3.64M in fiscal 2017.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$70.50M–
FY2024Dec 31, 2024-$30.05M–
FY2023Dec 31, 2023-$13.76M–
FY2022Dec 31, 2022-$39.68M–
FY2021Dec 31, 2021-$31.72M–
FY2020Dec 31, 2020-$39.45M–
FY2019Dec 31, 2019-$49.76M–
FY2018Dec 31, 2018-$45.70M-1356.5%
FY2017Dec 31, 2017$3.64M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$8.09M–
Q1 FY2026Mar 31, 2026-$4.09M–
Q4 FY2025Dec 31, 2025-$28.71M–
Q3 FY2025Sep 30, 2025-$11.34M–
Q2 FY2025Jun 30, 2025-$11.23M-4418.5%
Q1 FY2025Mar 31, 2025-$19.23M–
Q4 FY2024Dec 31, 2024-$13.43M–
Q3 FY2024Sep 30, 2024-$8.13M–
Q2 FY2024Jun 30, 2024$260.00K–
Q1 FY2024Mar 31, 2024-$8.75M–
Q4 FY2023Dec 31, 2023-$3.44M–
Q3 FY2023Sep 30, 2023-$2.11M–
Q2 FY2023Jun 30, 2023-$3.92M–
Q1 FY2023Mar 31, 2023-$4.28M–
Q4 FY2022Dec 31, 2022-$10.32M–
Q3 FY2022Sep 30, 2022-$8.26M–
Q2 FY2022Jun 30, 2022-$12.10M–
Q1 FY2022Mar 31, 2022-$9.01M–
Q4 FY2021Dec 31, 2021-$10.94M–
Q3 FY2021Sep 30, 2021-$7.23M–
Q2 FY2021Jun 30, 2021-$5.78M-584.5%
Q1 FY2021Mar 31, 2021-$7.77M–
Q4 FY2020Dec 31, 2020-$14.54M–
Q3 FY2020Sep 30, 2020-$13.13M–
Q2 FY2020Jun 30, 2020$1.19M–
Q1 FY2020Mar 31, 2020-$12.97M–
Q4 FY2019Dec 31, 2019-$9.29M–
Q3 FY2019Sep 30, 2019-$10.26M–
Q2 FY2019Jun 30, 2019-$17.93M-257.7%
Q1 FY2019Mar 31, 2019-$12.29M–
Q4 FY2018Dec 31, 2018-$11.55M–
Q4 FY2017Dec 31, 2017-$6.30M–
Q3 FY2017Sep 30, 2017$11.37M–
Q2 FY2017Jun 30, 2017-$3.12M–

More Aquestive Therapeutics figures

See a number that looks wrong?